2018•NeurologyRequires access

ODM-104 and Optimized Carbidopa Dose Show Beneficial Effect on Levodopa PK in Healthy Subjects (P6.028)

Johanna Tuunainen, Juha Ellmén, Mikko Vahteristo, Aila Holopainen, Denis Strugala

Abstract

To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa pharmacokinetics (PK) at 3 modified release (MR) levodopa strengths and to compare with a standard carbidopa/levodopa immediate release (IR) formulation.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Carbidopa, Levodopa, Medicine, Pharmacology, Internal medicine, Parkinson's disease, Disease